Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
EAST RUTHERFORD, N.J., April 26, 2018 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that first quarter 2018 financial results will be released on Thursday, May 3, 2018 before the market opens.
The Company will host a conference call to discuss the financial results.
| First Quarter 2018 Earnings Conference Call | |
| When: | Thursday, May 3, 2018 at 8:30 a.m. Eastern Time |
| Dial-in: | 1-877-260-1479 for U.S. |
| 1-334-323-0522 for International | |
| Passcode: 5093025 | |
| Dial-in Replay: | 1-888-203-1112 for U.S. |
| 1-719-457-0820 for International | |
| Passcode: 5093025 | |
| Available through Thursday, May 10, 2018 | |
| Webcast: | www.cambrex.com |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing. For more information, please visit www.cambrex.com.
| Contact: | Stephanie LaFiura |
| Investor Relations Associate | |
| Tel: 201-804-3037 | |
| Email: [email protected] |
